GLP-1 Receptor Agonist Evidence: Beyond Obesity & Diabetes
The EVOKE trial investigates oral semaglutide cognitive outcomes in early Alzheimer’s disease. This GLP-1 receptor agonist evidence expands understanding beyond obesity and diabetes. Results inform clinical decisions on semaglutide’s neuroprotective…
Distribution and Modulation of Endocannabinoid Enzymes in Post-Traumatic Headache
Post-traumatic headache endocannabinoid system changes are critical in understanding pain after mild traumatic brain injury. This study maps enzyme distribution in trigeminal and midbrain regions. Findings provide a foundation for potential…
Could Cannabis Edibles Help Manage Dementia Symptoms?
Cannabis edibles in dementia care are gaining attention for managing behavioral symptoms like agitation and sleep disturbances. Emerging research suggests potential benefits through neuroinflammation modulation. Cannabis edibles in dementia care offer a…
Alzheimer’s Risk Reduced After High-Dose Influenza Vaccination vs. Standard Dose, Study Finds
Neuroinflammation Alzheimer prevention is highlighted by a study showing reduced Alzheimer's risk with high-dose influenza vaccination. This vaccine offers stronger immune protection and lowers systemic inflammation. These findings support vaccination as…
New Research Project Explores Menopause in Women with MS
Menopause multiple sclerosis research is uncovering how hormonal transitions affect disease progression and symptom management in women. This new study focuses on neuroinflammation and hormonal changes unique to women with MS during menopause.…
Tetrahydrocoptisine alleviates postoperative delirium with sleep disturbances by modulating the TH/NLRP3 Inflammasome pathway.
Postoperative delirium sleep disturbances represent a significant challenge in perioperative neurocognitive health. This study investigates tetrahydrocoptisine's role in modulating the TH/NLRP3 inflammasome pathway to alleviate these symptoms. Findings…
Medicinal Cannabis Shows Efficacy for Alzheimer’s Palliative Care – Sechat
Cannabis palliative care Alzheimer's offers promising symptom management for agitation, sleep disruption, and appetite loss in dementia. Emerging evidence suggests cannabinoids may address neuroinflammation and behavioral symptoms. This approach supports…
CB2 Receptors in the Brain: A Promising but Unproven Anti-Inflammatory Target
CB2 receptor neuroinflammation is a promising target in neurodegenerative diseases such as Alzheimer's and Parkinson's. Preclinical studies show CB2 activation reduces brain inflammation and protects neurons. However, clinical evidence for CB2 receptor…
Advances in Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s
Amyloid beta aggregation Alzheimer's disease is a key pathological mechanism driving cognitive decline. This article reviews advances in targeting amyloid beta aggregation and neuroinflammation. Natural products like curcumin show potential but require…
Therapeutic Effects of a Sesquiterpene-Rich Cannabis Essential Oil on Neuroinflammation
This study highlights the effects of a sesquiterpene-rich essential oil cannabis on neuroinflammation and symptom relief in multiple sclerosis models. The essential oil acts through CB2 receptor pathways to provide neuroprotection. These findings suggest…